Literature DB >> 18471836

Epigenetic drivers and genetic passengers on the road to cancer.

Carla Sawan1, Thomas Vaissière, Rabih Murr, Zdenko Herceg.   

Abstract

Cancer is traditionally viewed as a primarily genetic disorder, however it is now becoming accepted that cancer is also a consequence of abnormal epigenetic events. Genetic changes and aneuploidy are associated with alterations in DNA sequence, and they are a hallmark of the malignant process. Epigenetic alterations are universally present in human cancer and result in heritable changes in gene expression and chromatin structure over many cell generations without changes in DNA sequence, leading to functional consequences equivalent to those induced by genetic alterations. Importantly, intriguing evidence emerged suggesting that epigenetic changes may precede and provoke genetic changes. In this scenario, epigenetic events are primary events while genetic changes (such as mutations) may simply be a consequence of disrupted epigenetic states. This fact may explain why many genetic screens proved to be limited with regard to cancer causality and pathogenesis. Aberrant epigenetic events affect multiple genes and cellular pathways in a non-random fashion and this can predispose to induction and accumulation of genetic changes in the course of tumour initiation and progression. These considerations are critical for a better understanding of tumourigenesis and molecular events underlying the acquisition of drug resistance, as well as development of novel strategies for cancer therapy and prevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471836     DOI: 10.1016/j.mrfmmm.2008.03.002

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  50 in total

Review 1.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

Review 2.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

3.  Microfluidic Low-Input Fluidized-Bed Enabled ChIP-seq Device for Automated and Parallel Analysis of Histone Modifications.

Authors:  Travis W Murphy; Yuan-Pang Hsieh; Sai Ma; Yan Zhu; Chang Lu
Journal:  Anal Chem       Date:  2018-06-08       Impact factor: 6.986

Review 4.  Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma.

Authors:  Yasushi Toh; Akinori Egashira; Manabu Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-03-26

Review 5.  Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases.

Authors:  Amir Abbas Momtazi; Giuseppe Derosa; Pamela Maffioli; Maciej Banach; Amirhossein Sahebkar
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

6.  Mechanisms by Which Pleiotropic Amphiphilic n-3 PUFA Reduce Colon Cancer Risk.

Authors:  Robert S Chapkin; Vanessa DeClercq; Eunjoo Kim; Natividad Roberto Fuentes; Yang-Yi Fan
Journal:  Curr Colorectal Cancer Rep       Date:  2014-12-01

Review 7.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

Review 8.  Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis.

Authors:  Yi Tian; Weibing Yang; Jianxun Song; Yuzhang Wu; Bing Ni
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

9.  Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer.

Authors:  Aditi Hazra; Charles S Fuchs; Takako Kawasaki; Gregory J Kirkner; David J Hunter; Shuji Ogino
Journal:  Cancer Causes Control       Date:  2010-03       Impact factor: 2.506

10.  Aberrant epigenetic silencing is triggered by a transient reduction in gene expression.

Authors:  Jon A Oyer; Adrian Chu; Sukhmani Brar; Mitchell S Turker
Journal:  PLoS One       Date:  2009-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.